Regeneron Pharmaceuticals, Inc. (BVMF:REGN34)

Market Cap	420.74B -4.9%
Revenue (ttm)	79.00B +1.0%
Net Income	24.81B +2.1%
EPS	228.47 +8.2%
Shares Out	n/a
PE Ratio	16.96
Forward PE	16.31
Dividend	0.22 (0.32%)
Ex-Dividend Date	Nov 18, 2025

Volume	1
Average Volume	1,305
Open	67.75
Previous Close	67.90
Day's Range	67.75 - 67.75
52-Week Range	44.82 - 73.33
Beta	0.39
RSI	52.93
Earnings Date	Jan 30, 2026

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 15,222
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: REGN34

Financial Performance

In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.

Financial numbers in USD